CLEARLIGHT™ ACNE TREATMENT ZAPS SAN DIEGO
The ClearLight system takes an entirely new approach to acne. Its high-intensity, narrow-band phototherapeutic light destroys the bacteria that cause acne, without damaging the surrounding skin. Safe for use on any body part or skin type, ClearLight effectively clears a high percentage of P. acnes lesions in just four weeks.
Acne is estimated to affect more than 80% of the world’s population at some time during their life. In the U.S., more than $1.4 billion is spent on anti-acne medications and treatments. Unfortunately, many topical and oral acne treatments are known to cause side effects such as redness, irritation, peeling or increased sensitivity to the sun. ClearLight is an important new treatment for acne because it is effective, painless and most importantly, has no known side effects.
Consider the following segment idea:
ClearLight Acne Treatment Zaps San Diego: San Diego-based physician, Dr. Mitchel P. Goldman, can demonstrate how the high-intensity light is used on a local resident to treat his/her acne. The segment might include on-the-street comments on acne. We can demonstrate how the machine works and how the patient feels about the procedure. We can also show before and after shots of the patient’s progress.
About Lumenis™
Lumenis™, the world leader in laser and light-based technologies for medical and aesthetic applications, was created on April 30, 2001 when ESC™ Medical Systems and Coherent Medical Group joined forces. Separately, ESC and Coherent Medical Group were both leaders and pioneers in the application of light to life-enhancing aesthetic and medical procedures. Together as Lumenis, they offer the widest range of products, an unparalleled product support system for their medical clientele, and, at $25 million, the largest investment for research and development in its industry.
For more information or to schedule an interview, please contact:
Brianna Konefall
Creative Media Marketing
323-935-9881
This article courtesy of http://www.tico1.org.
You may freely reprint this article on your website or in
your newsletter provided this courtesy notice and the author
name and URL remain intact.
